%0 Journal Article
%T Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema
%A Herth FJ
%A Ernst A
%A Baker KM
%A Egan JJ
%A Gotfried MH
%A Hopkins P
%A Stanzel F
%A Valipour A
%A Wagner M
%A Witt C
%A Kesten S
%A Snell G
%J International Journal of Chronic Obstructive Pulmonary Disease
%D 2012
%I 
%R http://dx.doi.org/10.2147/COPD.S31082
%X racterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema Original Research (1446) Total Article Views Authors: Herth FJ, Ernst A, Baker KM, Egan JJ, Gotfried MH, Hopkins P, Stanzel F, Valipour A, Wagner M, Witt C, Kesten S, Snell G Published Date July 2012 Volume 2012:7 Pages 397 - 405 DOI: http://dx.doi.org/10.2147/COPD.S31082 Received: 21 February 2012 Accepted: 28 March 2012 Published: 18 July 2012 Felix JF Herth,1 Armin Ernst,2 Kimberly M Baker,3 Jim J Egan,4 Mark H Gotfried,5 Peter Hopkins,6 Franz Stanzel,7 Arschang Valipour,8 Manfred Wagner,9 Christian Witt,10 Steven Kesten,11 Gregory Snell12 1Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, Germany; 2St Elizabeth's Medical Center, Boston, MA, USA; 3University of Iowa, Iowa City, IA, USA; 4Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, Ireland; 5Pulmonary Associates, Phoenix, AZ, USA; 6Lung Transplant Unit, Prince Charles Hospital, Chermside, Australia; 7Zentrum f¨¹r Pneumologie, Hemer, Germany; 8Ludwig-Boltzmann-Institute for COPD, Otto-Wagner-Hospital, Vienna, Austria; 9Klinikum N¨¹rnberg, N¨¹rnberg, Germany; 10Pneumology, Charit¨¦ Campus-Mitte, Berlin, Germany; 11Uptake Medical Corp, Tustin, CA, USA; 12Allergy Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Australia Introduction: Endoscopic lung volume reduction has been developed as a therapeutic option for advanced emphysema. Six-month results following treatment with endoscopic thermal vapor ablation (InterVapor ; Uptake Medical, Tustin, CA) were described previously, and here we report observations from the 12-month assessment. Methods: Two multicenter, international, single-arm trials of InterVapor (unilateral upper lobe treatment) in patients with upper lobe predominant emphysema were conducted. Inclusion criteria: forced expiratory volume in 1 second (FEV1) 15%¨C45% predicted, residual volume > 150%, total lung capacity > 100%, 6-minute walk distance (6MWD) > 140 m, and diffusing capacity for carbon monoxide > 20% predicted. Efficacy endpoints: spirometry, body plethysmography, lung volumes by high-resolution computed tomography, St George's Respiratory Questionnaire, modified Medical Research Council dyspnea scale, and 6MWD. All adverse events were collected and independently adjudicated. Results: Forty four patients were treated at a mean (standard deviation) age of 63 (5.6) years, FEV1 0.86 mL (0.25 mL) (n = 22 men and 22 women). Mean (standard deviation) changes from baseline at 12 months were: FEV1 86.2 mL (173.8 mL), St George's Respiratory Questionnaire -11.0 (14.0) units, treated lobar volume from high-resolution computed tomography -751.8 mL (653.9 mL), residual volume -302.8 mL (775.6 mL), 6MWD 18.5 m (63.7 m), and modified Medical Research Council dyspnea scale score -0.83 (0.97) (P < 0.05 for all except 6MWD). Improvements were numerically larger at 6 versus 12 months. GOLD stage III an
%K emphysema
%K bronchoscopy
%K lung volume reduction
%K thermal energy
%U https://www.dovepress.com/characterization-of-outcomes-1-year-after-endoscopic-thermal-vapor-abl-peer-reviewed-article-COPD